A groundbreaking study published in Research (2025, DOI: 10.34133/research.0545) has elucidated the molecular mechanisms by which protein phosphatase 2A (PP2A) regulates CD8+ T cell-mediated immune ...
CD8+ T cells divide cysteine between pathways that control growth and cancer-killing activity. Adjusting its use can enhance ...
Phase 1 Clinical Trial of EVOLVE104 Continues to Advance According to Plan Oral Minisymposium Presentation Demonstrates That EVOLVE T Cell Engagers Drive Greater T Cell Activation, Proliferation and ...
Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare ...
Over the past few decades, the idea of modifying a patient’s own immune cells to recognize and destroy cancer has evolved from concept to reality. So-called “adoptive T cell therapy” has emerged as ...
A detailed analysis of T-cell redirecting therapies in oncology, comparing the mechanisms of bispecific antibodies and CAR T ...
The MarketWatch News Department was not involved in the creation of this content. Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating ...
Scientific Advisory Board (SAB) includes experts in the development and approved T-cell engager therapies, supporting CAPTN-3’s advancement ...
An innovative type of CAR T cell therapy, called KIR-CAR, was shown to be safe, with increasing efficacy corresponding to higher doses of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results